MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.61 1.2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.02

Max

12.68

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+52.49% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.45%

Nākamie ieņēmumi

2026. g. 9. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-117M

251M

Iepriekšējā atvēršanas cena

11.41

Iepriekšējā slēgšanas cena

12.61

Ziņu noskaņojums

By Acuity

37%

63%

111 / 349 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. apr. 17:26 UTC

Galvenie ziņu notikumi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026. g. 7. apr. 23:55 UTC

Tirgus saruna

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026. g. 7. apr. 23:47 UTC

Tirgus saruna
Galvenie ziņu notikumi

Market Talk Roundup: Latest on U.S. Politics

2026. g. 7. apr. 23:47 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026. g. 7. apr. 23:44 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:37 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:15 UTC

Tirgus saruna
Galvenie ziņu notikumi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026. g. 7. apr. 23:01 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026. g. 7. apr. 22:58 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026. g. 7. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026. g. 7. apr. 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 7. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. apr. 19:45 UTC

Tirgus saruna

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026. g. 7. apr. 19:17 UTC

Galvenie ziņu notikumi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026. g. 7. apr. 19:16 UTC

Tirgus saruna

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026. g. 7. apr. 18:41 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026. g. 7. apr. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026. g. 7. apr. 18:39 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026. g. 7. apr. 18:24 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 17:08 UTC

Tirgus saruna

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026. g. 7. apr. 16:21 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

52.49% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  52.49%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

111 / 349 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat